Emtora Biosciences, Inc., a San Antonio-based biotech firm, has announced the acceptance of an abstract for oral presentation at the upcoming Digestive Disease Week Annual Meeting. This prestigious event gathers…
VirtualHealth is thrilled to announce that its HELIOS platform has been awarded the Bronze Stevie® Award in the Healthcare Technology Solution category at The 22nd Annual American Business Awards®. This…
AMRA Medical, along with Linköping University, has successfully completed the baseline enrollment for the pioneering ACCESS-ESLD study. This innovative study aims to provide rapid, non-invasive clinical surveillance for various conditions…
The “Oncology Collaboration and Licensing Deals 2019-2024” report, recently incorporated into ResearchAndMarkets.com’s offerings, presents an in-depth examination of 3685 oncology deals inked by leading biopharmaceutical companies worldwide between 2019 and…
The n-Lorem Foundation, a nonprofit organization dedicated to providing support and solutions for individuals afflicted with nano-rare diseases, has recently forged a significant partnership with Hongene Biotech Corporation. This collaboration…
“Concert Health and AIMS Center Join Forces to Expand Telepsychiatry Care” Concert Health, a leading Collaborative Care platform, and the AIMS Center at the University of Washington Department of Psychiatry…
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a leading oncology firm, revealed today that the European Commission (EC) has granted approval for tislelizumab as a treatment for non-small cell…
KKR, a prominent global investment firm, along with Impilo, a Nordic healthcare investment firm, has agreed to acquire Immedica Pharma, a Swedish-based pharmaceutical company specializing in rare diseases and specialty…
ImmunityBio, Inc. (NASDAQ: IBRX), a leader in immunotherapy, has just received FDA approval for ANKTIVA (N-803, or nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin (BCG). This approval marks a…
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical firm dedicated to pioneering treatments for neurological disorders and cardio-renal disease, has disclosed the dosing of the first patient in its relaunched…
Saghmos Therapeutics, Inc. (Saghmos), a privately owned biopharmaceutical firm, has disclosed its collaboration with the Duke Clinical Research Institute (DCRI) to enhance and strategize the implementation of Saghmos’ Phase 3…
Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a prominent biopharmaceutical company specializing in muscle diseases, has unveiled encouraging two-year topline results from the ARCH trial. The ARCH study, conducted at a single…